Waters Corporation (WAT) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $401.25. The rating moved from Neutral to Overbought on August 12, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$401.25
• Last changeMoved from Neutral to Overbought on August 12, 2026
• SectorHealthcare
• IndustryDiagnostics & Research

See all overbought Healthcare stocks →

AI analysis

Waters Corporation is well-positioned with market-leading chromatography and mass spec products, a high-margin aftermarket business, and direct readthroughs from expanding biologics, CRO/CDMO and diagnostic workflows. Near-term sentiment is constructive for growth-oriented scientific-instrumentation names, and Waters benefits from recurring consumables and services revenue that smooths instrument-cycle volatility. Key drivers include continued adoption in biologics analytics, stable cash generation to support R&D and capital returns, and incremental share gains from specialized applications. Performance will hinge on instrument order cadence and global lab capex trends.

Key factors

• Leading market position in chromatography and mass spectrometry with strong brand recognition in pharma, biotech, and analytical labs
• High-margin recurring consumables and service revenue that supports predictable cash flow and resilience in softer instrument cycles
• Readthrough from a biologics/CRO/CDMO supplier supercycle that should lift demand for analytical instruments and method development services
• Exposure to growing diagnostic and screening procedures that can drive higher instrument placements and aftermarket revenues
• Solid balance sheet and cash generation that enable R&D, bolt-on M&A, and share repurchases
• Constructive near-term market sentiment (risk-on) that favors growth-oriented, instrumentation names

Risks

• Cyclical capital spending by pharma and large labs; instrument orders can be lumpy and decline in a macro slowdown
• Intense competition from large scientific instrument players (e.g., Thermo Fisher, Agilent) leading to pricing pressure
• Supply chain disruptions or component shortages that delay instrument deliveries and revenue recognition
• Foreign-exchange volatility given meaningful international revenue
• Regulatory or reimbursement changes that indirectly affect lab budgets and hospital procurement cycles
• Valuation sensitivity — limited near-term upside if broader markets rotate away from growth names

Latest MarketMoodz coverage

• Waters CEO: China Rising as Biopharma Innovation Hub2026-05-05
• Waters stock climbs after FDA clears at-home cervical cancer screening kit2026-04-08

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.